P-Selectin Targeted Nanoparticles for Brain Metastasis Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current targeted therapies for cancers such as melanoma and BRCA-mutated breast cancer face challenges including drug resistance, limited brain penetration, and poor tumor accumulation, leading to ineffective treatment of brain metastases and aggressive tumor growth.
Innovation Solution
Development of polymeric nanoparticles with P-selectin targeting moieties that enhance delivery of therapeutically active agents, such as MEK and BRAF inhibitors, PARP inhibitors, and immune checkpoint inhibitors, to cancers with overexpressed P-selectin, facilitating targeted drug delivery across the blood-brain barrier and improving treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional targeted therapies are used to treat melanoma and other cancers, then tumor treatment efficacy is improved, but drug resistance develops leading to relapse and treatment failure
Solution Approach 1:
The patent segments the therapeutic approach by using nanoparticles as carriers that can deliver multiple drugs (BRAF inhibitors and MEK inhibitors) simultaneously to the tumor site, enabling combination therapy to overcome resistance mechanisms that develop against single-agent treatments
Solution Approach 2:
The nanoparticles are designed with targeting moieties that pre-functionalize them to specifically bind to P-selectin on tumor cells and endothelial cells, ensuring the drugs are delivered directly to the tumor before resistance can develop, thereby prolonging treatment response duration
2Reliability
If targeted therapies are administered to treat melanoma, then overall survival is improved, but adverse events cause treatment discontinuation
Solution Approach 1:
The nanoparticle acts as an intermediary carrier that protects the therapeutic drugs from systemic circulation, delivering them specifically to the tumor site through P-selectin targeting, thereby reducing exposure of healthy tissues to the drugs and minimizing adverse events while maintaining overall survival benefits
3Reliability
If targeted therapies are used to treat melanoma, then progression-free survival is improved, but acquired resistance through MAPK pathway reactivation occurs
Solution Approach 1:
The patent merges BRAF inhibitors and MEK inhibitors into a single nanoparticle delivery system, enabling simultaneous suppression of both targets in the MAPK pathway. This combination approach prevents resistance through MAPK pathway reactivation by blocking multiple points in the signaling cascade at once, thereby maintaining progression-free survival
4Reliability
If targeted therapies are administered to treat melanoma, then treatment response is improved, but brain penetration is limited rendering the brain a sanctuary for tumor cells
Solution Approach 1:
The nanoparticle serves as a mediator that facilitates drug transport across the blood-brain barrier by targeting P-selectin expressed on brain endothelial cells and tumor cells. This targeted delivery mechanism enables the drugs to reach brain metastases effectively, eliminating the brain as a sanctuary for tumor cells while maintaining overall treatment response
5Device complexity
If conventional drug delivery is used, then treatment is simple, but tumor accumulation is poor leading to ineffective treatment
Solution Approach 1:
The nanoparticle acts as a targeted intermediary carrier that actively delivers drugs to the tumor through P-selectin binding. This targeted delivery mechanism significantly enhances tumor accumulation of the therapeutic agents compared to conventional non-targeted delivery, ensuring effective treatment concentrations are achieved at the tumor site
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles improve drug penetration into the brain and tumors, enhancing treatment efficacy by overcoming resistance mechanisms and improving survival rates and reducing side effects.
Implementation Method 1
the polymeric matrix has attached to a surface thereof a P-selectin (SELP) selective targeting moiety
Data Source
AI summary
Particles made of a polymeric matrix having associated therewith a therapeutically active agent usable in treating a medical condition associated with an overexpression of P-selectin in a subject in need thereof and featuring a P-selectin selective targeting moiety represented by Formula I as defined and described in the specification and claims, compositions comprises these particles and uses thereof, are provided.